Recent advances in basic science pointed to a role for proteinases, through the activation of proteinase-activated receptors (PARs) 
Proteases can signal to cells through a variety of mechanisms. They can transform a pro-receptor or a proagonist into an active receptor or agonist respectively, by cleaving these molecules. They can act as any other agonist by binding to a receptor through their non-catalytic sites. Compelling evidence that has accumulated in recent years also indicates that certain proteases, such as thrombin, tryptase, and trypsin, can signal to cells through the activation of protease-activated receptors (PARs). PARs are activated by a unique mechanism that involves the proteolytic cleavage of their N-terminal extracellular domain. This cleavage, due to the action of diverse proteases, releases a new N-terminal domain that acts as a tethered ligand, binding the receptor itself on its second extracellular loop, to induce an intracellular signal ( Fig. 1) . Four members of the PARs family have been cloned. PAR 1 , PAR 3 and PAR 4 are considered as thrombin receptors since they have been shown to be responsible for thrombin-induced platelet activation. However, these receptors can also be activated by other proteases such as trypsin and cathepsin G for PAR 4 , coagulation factors Xa and VIIa for PAR 1 (Fig. 1) . Another member of this family, PAR 2 , is not activated by thrombin, but can be activated by trypsin and mast cell tryptase. Useful pharmacological tools have been raised to specifically activate those receptors: small synthetic peptides corresponding to the tethered ligand domain are able to activate selectively PAR 1 , PAR 2 and PAR 4 . Surprinsingly, PAR 3 cannot be activated by peptidic sequences corresponding to its tethered ligand domain, rendering the study of the physiological role of this receptor more difficult in the absence of selective agonist. The peptidic sequence corresponding to the human PAR 2 receptor, SLIGKV-NH 2 (where each letter correspond to the amino acid code), selectively activates the receptor (Fig. 1) , as does the SLIGRL-NH 2 peptide corresponding to the rat sequence. The tethered ligand sequence corresponding to the human PAR 1 receptor (SFLLR-NH 2 ; Fig. 1 ) is not selective for PAR 1 , but can also activate PAR 2 . A substitution of the serine amino acid by a threonine (TFLLR-NH 2 ) remarkably increases the specificity of the peptide for the PAR 1 receptor, and this later peptide is now used as a selective PAR 1 agonist. Peptide corresponding to the tethered ligand of PAR 4 (GYPGKV-NH 2 ; Fig. 1 ) is specific for PAR 4 , but is not a very potent agonist. Substitution of the first amino acid by an Alanine residue (AYPGKV-NH 2 ) considerably increases the potency of the agonist for PAR 4 activation and is now preferably used as a PAR 4 agonist. Fig. 1 : mechanism of activation of proteinase-activated receptors (PARs) by proteinases, four members of the family: PAR 1 , PAR 2 , PAR 3 and PAR 4 , proteinases responsibles for PARs activation (in blue) and tethered ligand peptidic sequences (red boxes) that can be use to activate each receptor.
PARs and inflammation
Several studies have shown the pro-inflammatory effects of acute activation of PAR 2 . First, we have shown that intraplantar injection of the selective PAR 2 -activating peptide SLIGRL-NH 2 caused edema and inflammatory cell recruitment (Vergnolle et al. 1999a) . Later, we have demonstrated that PAR 2 activation promotes the first signals for leukocyte recruitment to the site of inflammation, causing leukocyte rolling, adhesion and translocation across the wall of blood vessels (Vergnolle 1999) . In the skin, acute activation of PAR 2 leads to skin inflammation and PAR 2 activation has been implicated in the generation of inflammatory signs associated with contact dermatitis (Seeliger et al. 2003) . A recent study by Ferrell et al. (2003) , has also demonstrated a prominent role for PAR 2 in an animal model of monoarthritis, PAR 2 -deficient mice did not developed signs of chronic inflammation. In the gut, acute activation of PAR 2 caused colitis characterized by gut wall edema, granulocyte recruitment, increased permeability and release of pro-inflammatory cytokines such as interleukin-1 and TNF-α (Cenac et al. 2002) . In the airways, the role of PAR 2 is controversial. Although studies have shown that PAR 2 -activating peptides caused relaxation of isolated airways and was protective against bronchoconstrictor challenge (Cocks et al. 1999) , other studies have shown that mice that lack functional PAR 2 showed extensive allergic response compared to wild-type mice, suggesting a prominent pro-inflammatory role for PAR 2 activation in airway diseases (Schmidlin et al. 2002) . Similar controversies also exist in the gut, where chronic and systemic treatment with PAR 2 agonist was protective against a chronic model of inflammatory bowel disease (Fiorucci et al. 2001) , while acute activation of PAR 2 in colonic tissues led to inflammation (Cenac et al. 2002) . Overall, PAR 2 is present in many cells involved in inflammation (endothelial cells, mast cells, neutrophils, eosinophils, epithelium, etc.), and its activation on those cells provokes the release of many inflammatory mediators (prostaglandins, nitric oxide, cytokines, etc.), further supporting the idea that PAR 2 activation plays a prominent role in inflammatory pathologies (Vergnolle 2000 (Vergnolle , 2001b .
Several studies have also shown a pro-inflammatory role for PAR 1 activation (Cirino et al. 1996 ,Vergnolle et al. 1999b , and most recently, we have demonstrated that PAR 4 agonists induced oedema and granulocyte infiltration when injected into the rat paw (Hollenberg et al. 2004 ).
PARs on sensory neurons
Investigating the mechanisms of PAR 2 -induced inflammation, we have discovered that the receptor was present on sensory nerves, where its activation was able to cause the release of neuropeptides such as substance P and CGRP (Steinhoff et al. 2000) . This PAR 2 -induced neuropeptide release was responsible for the edema observed after intraplantar injection of PAR 2 agonists, but not for granulocyte recruitment to the site of inflammation (Steinhoff et al. 2000) . Other studies have shown that the effects of PAR 2 agonists on chloride secretion, mucus secretion in the gastro-intestinal tract, or coronary vasodilatation, were mediated by a mechanism involving activation of C-fibers (Green et al. 1999 , Kawabata et al. 2001 , McLean et al. 2002 . These results suggest that direct activation of PAR 2 on sensory neurons, and particularly on C-fibers, is responsible for different pathophysiological changes associated with inflammation, including a neurogenic inflammatory response.
PAR 1 was also found present on sensory neurons (de Garavilla et al. 2001 ), but its activation failed to release neuropeptides in the different tissues observed. However, neuropeptide receptor antagonists were able to significantly reduce PAR 1 agonist-induced oedema (de Garavilla et al. 2001) . Taken together, these results suggest that PAR 1 activation leads to inflammation through a pathway that involves a neurogenic mechanism that might be indirectly activated after PAR 1 activation. The role of PAR 1 activation in inflammation seems to be linked to activation of PAR 1 on other cell types than sensory neurons.
PAR 4 was also found present on peripheral neurons (D' Andrea et al. 2003) . However, the functionality of PAR 4 on those cells has never been investigated.
Involvement of PAR 2 activation in inflammatory hyperalgesia
The presence and functionality of PAR 2 on sensory neurons led us to investigate whether or not PAR 2 activation was implicated in inflammatory nociceptive pathways. Since PAR 2 agonists caused inflammation, we first defined doses of PAR 2 agonists that did not cause any signs of inflammation, by following oedema, granulocyte recruitment, prostaglandin release and blood flow (Vergnolle et al. 2001a ). Then, we used this sub-inflammatory dose to investigate whether or not it was capable of inducing hyperalgesia in response to a thermal or mechanical stimulation. Intraplantar injection of PAR 2 -activating peptide, trypsin or mast cell tryptase at doses that did not cause inflammation, provoked thermal and mechanical hyperalgesia. The same injections also caused activation of nociceptors at the spinal level, as followed by an increased fos expression in the superficial laminae (I and II) of the dorsal horn (Vergnolle et al. 2001a ). Moreover, this study showed that PAR 2 -deficient mice developed significantly less inflammatory hyperalgesia in response to intraplantar injection of formalin or the mast cell degranulator compound 48/80 (Vergnolle et al. 2001a ). The PAR 2 agonistmediated hyperalgesia was dependent on a mechanism involving central activation of neurokinin-1 receptors, release of pre-pro tachykinins and release of prostaglandins (Vergnolle et al. 2001a ). More recently, we have shown that activation of PAR 2 was able to potentiate responses of TRPV1 receptors to capsaicin (Amadesi et al. 2004) . In that study, we showed through both a pharmacological and gene-deletion approach that TRPV1 was implicated in PAR 2 -induced thermal hyperalgesia. We showed that PAR 2 -induced thermal hyperalgesia was inhibited by the TRPV1 antagonist capsazepine, and completely abolished in TRPV1-deficient mice, while PAR 2 -induced mechanical hyperalgesia was not changed by TRPV1 deficiency or antagonist treatments. Further, this study showed that TRPV1 activation in dorsal root ganglia neurons was po-tentiated by pre-exposure of those neurons to PAR 2 agonists, and this potentiating mechanism was PKC-dependent (Amadesi et al. 2004 ). Other studies also suggest the involvement of PAR 2 in visceral pain (Hoogerwerf et al. 2001 . Colonic or pancreatic activation of PAR 2 was shown to be responsible for activation of nociceptors at a spinal level and in the case of colon, PAR 2 agonists were able to induce long-lasting visceral hyperalgesia. In vitro studies showing that activation of PAR 2 on peripheral neurons provoked calcium mobilization (Steinhoff et al. 2000) , but also long-lasting hyperexcitability (Reed et al. 2003) , suggest that the hyperalgesic effects of PAR 2 agonists are due to the direct activation of the receptor on sensory neurons. However, the fact that PAR 2 agonists provoke the release of different mediators (prostaglandins, cytokines, etc.) in different cell types (endothelial cells, leukocytes, etc.) needs also to be considered in the context of inflammatory pain. PAR 2 activation might also participate to inflammatory pain by inflammatory mediators-induced sensitization of sensory neurons.
Thrombin receptor activation: new analgesic pathways?
Peripheral activation (intraplantar injections) by thrombin or a selective activating peptide of the thrombin receptor PAR 1 , provoked an increase in nociceptive threshold to thermal and mechanical stimulus (Asfaha et al. 2002) . This anti-nociceptive effect observed in basal conditions was reproduced in inflammatory conditions after carrageenan intraplantar injection (Asfaha et al. 2002) . Another study has shown recently that spinal activation of PAR 1 inhibited NMDA-induced nociceptive activity through a mechanism dependent on endothelin A (Fang et al. 2003) . Because PAR 1 activation on sensory neurons causes calcium mobilization, one can doubt that PAR 1 agonists exert their anti-nociceptive effects by direct activation of sensory fibers. Further studies on the signaling pathways and electrical responses of sensory neurons to PAR 1 agonists are needed to fully understand such mechanism.
Conclusions
Studies have shown that PAR 1 , PAR 2 and PAR 4 are present on peripheral neurons. The fact that PAR 2 activation can induce neurogenic inflammation and participate to the generation of inflammatory pain present PAR 2 as a valuable target for the treatment of inflammation and pain (Fig. 2) . PAR 1 activation also leads to inflammation with a neurogenic component. However, PAR 1 activation is also associated with analgesic response and inhibition of inflammatory hyperalgesia, presenting PAR 1 as a mediator that could exert dual activity in inflammatory pain mechanisms.
In conclusion, it appears that recent advances in basic science pointed to a crucial role for proteinases and their receptors in inflammatory hyperalgesia. We need to consider proteinases not only as digestive or degradative enzymes, but as signalling molecules that actively participate to several clinical symptoms associated with inflammatory diseases. de Garavilla L, Vergnolle N, Young SH, Ennes H, Steinhoff M, Fig. 2 : signals of proteinase-activated receptors, PAR 1 , PAR 2 and PAR 4 activation to sensory neurons and their known pathophysiological consequences. Activation of PAR 2 on sensory neurons leads to neurogenic inflammation through the release of neuropeptides, and to pain and hyperalgesia through the sensitization of TRPV1 receptor, thus highlighting PAR 2 as an interesting target for inflammation and pain therapies. PAR 1 activation on sensory neurons also provokes a neurogenic inflammation in certain tissues, through the release of neuropeptide, but low doses of PAR 1 agonists inhibit inflammatory hyperalgesia and caused analgesia, thereby suggesting dual and opposite effects in inflammation and pain.
